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Patients with inoperable pancreatic cancer have a dismal prognosis with a mean life expectancy of 3–6 months. New treatment
modalities are thus urgently needed. Telomerase is expressed in 85–90% of pancreas cancer, and immunogenic telomerase peptides
have been characterised. A phase I/II study was conducted to investigate the safety, tolerability, and immunogenecity of telomerase
peptide vaccination. Survival of the patients was also recorded. Forty-eight patients with non-resectable pancreatic cancer received
intradermal injections of the telomerase peptide GV1001 at three dose levels, in combination with granulocyte–macrophage colony-
stimulating factor. The treatment period was 10 weeks. Monthly booster vaccinations were offered as follow-up treatment. Immune
responses were measured as delayed-type hypersensitivity skin reaction and in vitro T-cell proliferation. GV1001 was well tolerated.
Immune responses were observed in 24 of 38 evaluable patients, with the highest ratio (75%) in the intermediate dose group.
Twenty-seven evaluable patients completed the study. Median survival for the intermediate dose-group was 8.6 months, significantly
longer for the low- (P¼0.006) and high-dose groups (P¼0.05). One-year survival for the evaluable patients in the intermediate dose
group was 25%. The results demonstrate that GV1001 is immunogenic and safe to use. The survival data indicate that induction of an
immune response is correlated with prolonged survival, and the vaccine may offer a new treatment option for pancreatic cancer
patients, encouraging further clinical studies.
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Pancreatic cancer is a highly lethal disease and little therapeutic
progress has been achieved in the last decades. Vaccination against
cancer is currently tested in many clinical trials as a new treatment
modality. In pancreatic cancer, few molecularly characterised
antigens have so far been available for use in vaccines. However,
the catalytic subunit of telomerase, hTERT, expressed in 85–90%
of human cancer tissues (Vasef et al, 1999) and an attractive
‘universal’ tumour antigen (Autexier, 1999), is also expressed in
pancreatic cancer where it has been used diagnostically (Suehara
et al, 1998; Uehara et al, 1999). By turning on hTERT and
telomerase activity, cancer cells are enabled to maintain functional
telomeres at the end of chromosomes, and are prevented from
going into senescence. Telomerase is consequently a key enzyme in
the process of immortalisation of cancer cells and has a pivotal role
in carcinogenesis.
It is well established that T cells of the human immune system
can recognise hTERT peptides, and a number of HLA-class I and
class II epitopes have been characterised (Vonderheide et al, 1999;
Minev et al, 2000; Arai et al, 2001; Vonderheide et al, 2001;
Hernandez et al, 2002; Scardino et al, 2002; Schroers et al, 2002,
2003; Gross et al, 2004). Recently it has also been reported that
telomerase-specific CD4þ and CD8þ T-cell responses are
induced upon vaccination with hTERT-transfected dendritic cells
(Su et al, 2005). Vaccination with the telomerase peptide GV1001
was recently shown to induce T-cell responses in patients with
non-small cell lung cancer (Brunsvig et al, 2006).
hTERT is expressed in some normal tissues, including
embryonic cells, bone marrow stem cells (Uchida et al, 1999)
and epithelial cells in colonic crypts (Tahara et al, 1999). Safety is
therefore an important issue in the development of telomerase-
targeted therapies. In general, telomerase activity is highly
overexpressed in malignant cells, compared to normal cells
(Tahara et al, 1999). This may provide the necessary window of
opportunity for the immune system to discriminate between
tumour cells and normal cells. Previous reports indicate that
telomerase-specific T cells capable of killing telomerase-positive
target cells did not kill CD34þ bone marrow stem cells
(Vonderheide et al, 1999), and that induction of telomerase-
specific T-cell responses in cancer patients is safe (Parkhurst et al,
2004; Vonderheide et al, 2004; Su et al, 2005).
Based on our earlier experience with vaccination with mutant
RAS peptides (Gjertsen et al, 2001), a protocol for telomerase
peptide vaccination of patients with non-resectable pancreatic
cancer was developed. The telomerase peptide used in this study,
GV1001; hTERT (611–626) is a promiscuous HLA class II epitope,
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vaccine that may, in contrast to many other peptide-based
vaccines, be administered without prior HLA typing of the
patients. Most tumours do not express HLA class II molecules
on their surface but HLA class II restricted CD4þ T cells are
nevertheless considered to be mandatory for establishing and
maintaining a clinically efficient anticancer immune response
(Mumberg et al, 1999; Schurmans et al, 2001).
The objectives of the present clinical trial and for the follow-up
protocol were to investigate the safety and tolerability of GV1001
administration, to determine the optimal dose for immunological
response, and register survival.
PATIENTS AND METHODS
Patient selection
Forty-eight treatment naive patients with non-resectable, histolo-
gially confirmed adenocarcinoma of the pancreas were enrolled in
the study (September 2000–March 2003). Karnofsky performance
status was 470%. Bone marrow, liver, heart and renal function
adequate, and age range 18–75 years. Forty-eight patients were
enrolled and sequentially divided into three groups, given either a
low dose (n¼11), an intermediate dose (n¼17), or a high dose of
the vaccine (n¼20). For details see Table 1.
Patients who received at least six vaccinations over 4 weeks were
considered evaluable for assessment of immune responses and
survival. The distribution of the evaluable patients was eight, 16,
and 14 in the low-, intermediate-, and high-dose groups,
respectively. The trial was approved by the regional ethics
committee and performed in compliance with the Declaration of
Helsinki Principles.
Vaccine and control peptides
The vaccine is a sterile lyophilised product consisting only of the
synthetic peptide GV1001; EARPALLTSRLRFIPK, corresponding
to the hTERT (611–626) fragment. GV1001 is a promiscuous HLA
class II epitope (Figure 1) and was selected after a preclinical
screening program. GV1001 was supplied by Avecia Biotechnol-
ogy, Cheshire, England. The vaccine was manufactured in
compliance with cGMP by Isopharma AS, Kjeller, Norway, and
released for clinical use by GemVax AS, Porsgrunn, Norway. Two
synthetic peptides, PEP 544; LMSVYVVELLRSFFYVTE (hTERT
(548–566)) and PEP 508; LLDILDTAGHEEYSAMRDQ (KRAS
(52–70) Q61H), were used as negative controls in the in vitro T-
cell proliferation assays used to monitor T-cell response in blood
samples from the vaccinated patients. The control peptides were
supplied by The Corporate Research Centre, Norsk Hydro,
Porsgrunn, Norway.
Recombinant human telomerase reverse transcriptase
Recombinant hTERT (563–735) was cloned in frame with the
N-terminal 6  His tag in Escherichia coli expression vector
pET28b(þ) (Novagen, Darmstadt, Germany). The protein was
produced in E.coli BL21 Codon Plus (DE3)-RIPL (Stratagene, La
Jolla, CA, USA), purified by NiNTA chromatography under
denaturing conditions (Qiagen, Hilden, Germany) and tested by
Western blot analysis with anti-His antibodies (Qiagen) and
Rabbit anti-Mouse Ig HRP (DakoCytomation, Glostrup, Denmark).
The positive fraction was dialysed in Slide-A-Lyzer
s Dialysis
Casette 10000 MWCO (Pierce, Rockford, IL, USA) against MQ-
water and sterile filtered before use.
Treatment protocol
A comprehensive assessment of adverse drug reactions,
blood screening, physical examination, and assessment of
Karnofsky performance status was performed at baseline and at
each visit.
The vaccine was administered by intradermal (i.d.) injection in
the right para-umbilical area following the schedule; three
injections in week 1 (Monday, Tuesday, and Friday) and one
weekly injection in weeks 2, 3, 4, 6, and 10. The three different
doses of vaccine administered were; low dose: 60nmole (112mg)
GV1001 in 0.10ml saline, intermediate dose: 300nmole (560mg)
GV1001 in 0.125ml saline, and high dose: 1.0mmole (1.87mg)
GV1001 in 0.20ml saline. From 5 to 15min before each vaccine
injection, 30mg granulocyte–macrophage colony-stimulating fac-
tor (Leucomax
s; Schering-Plough, Cork, Ireland) in 0.10ml saline
was injected i.d. at the vaccination site. After finishing the primary
protocol eighteen evaluable patients entered the follow-up study.
Monthly booster vaccination was offered, for up to 1 year starting
with patient no. 12 in the low-dose group. The patients were given
vaccine doses identical to the ones they received in the initial
protocol. The follow-up treatment was given to patients in good
general health.
Delayed-type hypersensitivity
Delayed-type hypersensitivity (DTH) skin test was performed at
visit one (baseline) and at all visits from week 2 and onwards. As
DTH test 60nmole (112mg) GV1001 in 0.10ml saline was injected
i.d. in the left para-umbilical area. A positive DTH test was defined
as a X5mm diameter erythema/induration 48h after the
administration. The patients were instructed to measure and
record the erythema/induration and report the result to the
clinician.
Monitoring of T-cell responses
At baseline and at weeks 6 and 10, 50ml of Acid Citrate Dextrose-
blood was sampled to assess changes in in vitro proliferative
GV1001-specific T-cell responses. Proliferation was measured
as count per minutes (c.p.m.) after incubation and uptake of
3H-thymidine in the standard proliferation assay described below.
A stimulatory index (SI) (c.p.m. with GV1001 divided by c.p.m.
without GV1001) X2 was considered as a positive T-cell response
to GV1001. PBMCs were isolated from peripheral blood using
density centrifugation over Ficoll–Hypaque (Lymphoprep;
Nycomed, Oslo, Norway), washed and frozen in RPMI-1640
(Gibco, Paisley, UK) with 20% FCS (PAA Laboratories GmbH,
Paching, Austria) and 10% DMSO and stored in liquid N2.
Following the inclusion of patient number 211, FCS was
substituted by 100mgml
 1 (10%) Human Albumin, owing to the
generation of high background proliferative responses against
antigens present in FCS. In the in vitro T-cell assay used here,
specific T cells were expanded from PBMC by two cycles of
antigen-driven stimulation before assaying. Samples harvested
before and after vaccination were processed in parallel. No
responses were observed in PBMC from normal blood donors
using this procedure. Thawed PBMC were seeded at 1 10
6 per
well in 24-well plates (Costar, Cambridge, MA, USA) in 1ml of
RPMI-1640 containing 15% heat-inactivated human serum and
antibiotics supplemented with GV1001 or control peptides at 25mM
concentration. After 3 days of culture the medium was supple-
mented with 10Uml
 1 of recombinant human interleukin-2
(Amersham, Aylesbury, UK). Cultured cells were re-stimulated
for one more cycle after 7–9 days of culture and finally tested on
days 14–18 for specific proliferating capacity against GV1001 and
control peptides at 25mM concentration, by using 5 10
4 T cells
and autologous, irradiated (30Gy) PBMCs (5 10
4cellswell
 1)a s
antigen-presenting cells (APCs). After 2 days, wells were pulsed
with 3.7 10
4Bq of
3H-thymidine over night and counted. Values
are given as mean c.p.m. from triplicate wells. Cytokine production
by responding T cells was measured in supernatants taken from
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cytokine kit and the Bio-Plex instrument (BioRad Laboratories
Inc., Hercules, CA, USA), as described by the manufacturer. Data
are given as picogram cytokineml
 1 and are calculated based on
standard curves for each of the cytokines. At baseline, responses
against either purified protein derivative of M. tuberculosis;
The Veterinary Institute, Oslo, Norway) or superantigen (SEC-3;
Toxin Technology, Sarasota, FL, USA) were also assessed in a
7-day assay, without Il-2, as a measure of general immune
status. GV1001-specific T cells from responding patients were
cloned by limiting dilution as described previously (Gjertsen et al,
1997).
Safety and toxicity
The patients were followed closely for signs of adverse events
during and after each vaccination. Adverse events were recorded
using the WHO toxicity criteria.
Table 1 Characteristics, summary of treatment and immune responses, and survival for the individual patients
Characteristics (baseline) Treatment weeks 1–12 Follow-up and survival
Dose group Patient No.
Age
(sex)
KPS
(%)
Tumour site/
metastasis
a
(+/ )
No. of Injections/
Completed study
Immune-
responses
DTH/T cells
No. of booster
injections DTH
Survival days
from start of
treatment
Low 1 69 (M) 85 cap/+ 6/no  /  —— 2 8
2 69 (M) 100 cap/  8/yes +/  — — 144
3 64 (M) 80 cap, cor/  7/no  /  —— 4 0
4 61 (F) 70 cap/+ 8/yes  /  — — 190
5 61 (M) 100 cau, cor/+ 6/no  /  —— 3 1
7
b 60 (F) 85 cau, cor/+ 5/no  /  —— 2 0
8 59 (F) 85 cap/+ 8/yes +/  — — 146
9
c 37 (M) 85 cor/+ 6/no  /  —— 9 4
10
b,d 59 (F) 100 cap/  4/no  /  — — 290
11
b 47 (M) 70 ?/+ 1/no  /  —— 3
12 59 (M) 100 cap/  8/yes +/  3   243
Intermediate 101 73 (F) 95 cap/+ 8/yes +/ 
e 6 + 325
102 55 (F) 95 cor, cau/  8/yes +/+ 7 + 362
103 58 (F) 95 cap/+ 8/yes +/  2   133
104 64 (F) 95 cap/  8/no  /+ — — 68
105 58 (M) 95 cap/+ 8/yes +/+ 3 + 189
106 49 (M) 85 cor/+ 7/no  /  —— 8 0
107 73 (M) 85 cau/+ 8/no  /  — — 132
108 56 (M) 95 cap/+ 8/yes +/+ 10 + 381
109
c 68 (M) 95 ?/? 6/no  /nt — — 228
110 59 (M) 90 cor, cau/  8/yes  /  4   292
111 68 (M) 100 cap/  8/yes  /+ 2   337
112 67 (F) 95 cap/  8/yes +/+ 1   199
113 58 (M) 95 cap/  8/yes  /+ 2 + 432
114
b 71 (F) 95 cau/+ 5/no  /nt 23
115 60 (F) 90 cap/  8/yes +/+ 13 + 575
116 66 (F) 95 cau/  8/yes +/+ 6   323
117 69 (M) 90 cap/  8/yes +/  —— 9 1
High 201 45 (F) 80 cap/  10/yes +/+ — — 320
202 58 (M) 85 cor, cau/  8/yes +/+ — — 165
203
b 54 (F) 85 cap/+ 2/no  /nt — — 27
204 70 (F) 90 cap/+ 7/no  /nt — — 53
205
b 42 (F) 70 cap/+ 4/no  /nt — — 10
206
b 49 (M) 75 cor, cau/+ 4/no  /nt — — 12
207 58 (F) 95 cap/  8/no  /  —— 8 2
208 75 (M) 95 cap/  8/yes  /+ 6   307
209 54 (M) 80 ?/? 8/yes  /+ 121
210 53 (F) 85 cor/+ 7/no  /  75
211 73 (M) 95 cor/  8/yes  /  4   249
212
b,f 40 (F) 90 cor/  8/yes  /+ 1   120
213
b,f 68 (F) 95 cap/  8/yes +/+ 3   176
214 56 (M) 85 cor/  8/yes  /  2 + 154
215 64 (M) 90 cap/  8/yes  /+ — — 119
216 58 (M) 90 cap/  8/yes  /+ 1   153
217
b 63 (M) 75 cap/+ 4/no  /  —— 1 2
218 46 (M) 90 cap/  8/yes  /+ — — 106
219 72 (F) 95 cor/+ 8/yes  /+ 8   365
221 70 (F) 95 cap, cor/  8/yes +/+
e 5 + 233
DTH¼delayed-type hypersensitivity; KPS¼Karnofsky performance status; nt¼not tested; na¼not applicable; cap¼caput; cau¼cauda; cor¼corpus; ?¼unknown.
a81% of
patients with metastasis had liver metastasis.
bNot evaluable.
cWithdrawn to other treatment after week 4.
dWithdrawn to surgery.
ePositive at base line.
fEarlier resected patient.
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Data from all patients who received GV1001 vaccination were
included in the safety analysis. All patients that completed visit six
(week 4) and complied with the inclusion criteria, were considered
as evaluable and were included in the analysis of immune response
and survival. Survival values are given as median and 95%
confidence interval. Differences between survival of immune
responders and non-responders, and between different treatment
groups, were tested by log-rank test.
RESULTS
A summary of individual patient’s characteristics and results are
given in Table 1.
Adverse events
GV1001 was administered on an outpatient basis and was well
tolerated in all the 48 patients that received at least one dose of
vaccine. In total 424 vaccine doses were administered during this
trial (1–21 doses per patient). In addition 354 DTH injections were
given. No sign of toxicity or clinically severe adverse events related
to the treatment was observed in any of the treated patients,
including long-term survivors who received 14–21 injections. All
patients reported at least one treatment related injection site
disorder such as erythema or induration. Observed drug related
side effects were fever (2%), chills (10%), pain (6%), fatigue (2%)
nausea (12%), and vomiting (2%). The frequency of patients with
adverse events in the three dose groups was five out of 11 (45%),
seven out of 17 (41%), and two out of 20 (10%). The number of
drug related adverse events were six, 22, and four in the low-,
intermediate-, and high-dose group, respectively. The intermediate
group received more injections and were followed up for a much
longer period owing to their prolonged survival. This probably
explains a higher total number of adverse events in this group.
Characterisation of immune responses against GV1001
Patients with a positive DTH test or the presence of GV1001-
specific T cells in peripheral blood after vaccination were
considered as immune responders. Figure 2 shows that induction
of detectable immune responses was dependent on vaccine dose.
The highest percentage of responding patients was observed in the
intermediate dose group, where 75% of the evaluable patients
responded (Figure 2A). The difference in the number of immune
responders observed in the three dose groups was not statistically
significant. The results also indicate that detectable immune
responses, as measured by DTH were induced more rapidly in the
patients receiving the intermediate dose (Figure 2B). No in vitro
T-cell responses were seen in the low-dose group (Table 1). The
in vitro immune responses detected in the intermediate dose group
were both more frequent and more vigorous than in those of the
high-dose group (data not shown). Examples of the kinetics of the
T-cell response, as measured by in vitro T-cell proliferation for
four individual patients in the intermediate group are given in
Figure 3. Enumeration of specific T cells is not possible with the
approach used here and is complicated by the fact that a large
number of different HLA class II molecules probably are involved.
However, the requirement for in vitro antigen driven expansion
before testing indicate that a relatively low number of GV1001-
specific T cells were present in circulation at the time of harvesting
of PBMC.
Overall, a vaccine related immune response was detected in 63%
of the evaluable study population. Patient nos. 101 and 221
demonstrated a pretreatment immune response to GV1001, patient
no. 101 with both DTH and T-cell response and patient no. 221
with DTH response.
The observed discrepancy between DTH reactions and T-cell
responses in vitro might either reflect different sensitivities in the
two assays or be a result of biologically different immune reactions
being generated. Thus, a shift in cytokine production away from
classical inflammatory cytokines might result in a lack of DTH
reaction. To further address the latter possibility, we first
investigated the cytokine profile generated against GV1001 by
peripheral blood T cells from two patients with different immune
reactions. Patient 101 from the low-dose group was DTH-positive,
but no proliferative response was detected in peripheral blood.
Patient 212 from the high-dose group was DTH-negative but
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Figure 1 In vitro stimulation of GV1001-specific T-cell clones from
patient no 102 (clone 22) and 105 (clones 6, 35, 51). Clones were
stimulated with GV1001 (25mM) pulsed onto APCs homozygous for
different HLA-class II molecules as indicated. Results are presented as c.p.m.
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Figure 2 Type and percentage of immune responders in patients
vaccinated with low, intermediate, and high dose GV1001 (A) and kinetics
of immune responses in the three dose groups, as measured by DTH
response (B). Bars show accumulated responses in each group.
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B demonstrate that cytokines are specifically produced upon
stimulation with GV1001 in samples harvested in week 10
following vaccination in both patients. Only background levels
were seen in prevaccine samples. Although the cytokine levels in
the sample without detectable proliferation was lower, the cytokine
profiles of the two samples were identical. Interestingly, both
patients displayed a broad profile with cytokines belonging to both
the Th1 and Th2 type. This indicates that the absence of a DTH
reaction in patient 212 is not owing to a switch from a Th1 profile
to a Th2 profile. To further investigate the relationship between
GV1001 dose and T-cell response, T cells from one responding
patient were cloned (patient no. 102). As demonstrated in Figure 5,
the proliferative response of the CD4þ Th clone TLC1 is
represented by a bell-shaped curve peaking at a GV1001
concentration of 1.5nM of GV1001. At 1000nM, the response was
reduced to about 20% of the peak response, indicating that high
GV1001 doses may result in tolerance or anergy induction.
Identical results were obtained with several T-cell clones derived
from patients with non-small cell lung cancer vaccinated with
GV1001 (data not shown). Interestingly these T-cell clones use
different T-cell receptors and are restricted by different HLA class
II molecules, indicating that this is a general, rather than anecdotal
finding.
As hTERT may be processed to peptides in many different ways,
and the binding motifs of different class II molecules are different,
it was important to investigate if different T-cell clones were also
capable of recognising hTERT fragments generated by feeding
recombinant hTERT to APCs. The three CD4þ Th cell clones
derived from patient 102 and 105 all recognised autologous PBMC
that were pulsed with recombinant telomerase protein (Figure 6A).
As the HLA class II molecules presenting the hTERT epitope
to the T-cell clones were different ( DQ,  DR, and  DP) and
the three clones have different fine-specificity (results not
shown), these results strongly suggest that natural processing of
hTERT may give rise to many different peptide fragments, fitting
into multiple HLA class II molecules.
For ethical reasons it is difficult to get tumour biopsies from
patients with inoperable pancreatic cancer for other than
diagnostic purposes. It is also generally difficult to establish even
short-term cell lines from such patients, should a biopsy be
available. For this reason, we were, with one exception, unable to
investigate if GV1001-specific T cells from this series of patients
were capable of recognising their autologous tumour cells. Several
CD4þ Th clones were expanded from blood sampled from patient
no. 105 in week 10 after vaccination. At a later stage patient no. 105
developed ascites and a T-cell depleted mononuclear cell suspen-
sion was prepared from the ascites. This cell suspension, also
containing tumour cells, was irradiated and tested for its capacity
to stimulate autologous GV1001-specific Th cell clones. The results
shown in Figure 6B demonstrate that the ascites cells were
recognised both by T-cell clones restricted by HLA-DP4 and -DQ6
to the same extent as the autologous APCs pulsed with GV1001.
These results strongly indicate that the T cells recognise either a
GV1001 equivalent epitope expressed by the tumour cells
themselves or cross-presented by APCs present in the ascites fluid.
Dose-related survival and correlation with immune
response
Although survival was not a primary endpoint in this study, we
had the opportunity to follow the included patients for survival,
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Figure 3 In vitro T-cell responses against GV1001 in blood samples harvested before (week 1), during and after vaccination (weeks 2, 3, 4, 6, and 10).
Responses are given as SI. Control cultures were primed and stimulated with control peptide PEP 544 or PEP 508.
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The survival curves for the three dose groups are presented in
Figure 7A, demonstrating a significantly increased survival in the
intermediate dose group compared to the other groups (inter-
mediate vs low: P¼0.006, intermediate vs high: P¼0.05). The
median survival for the low, intermediate, and high-dose groups
were, 4.0, 8.6, and 5.1 months, respectively. No statistically
significant difference was observed between the low- and high-
dose group.
The survival of the whole evaluable study population, divided in
immune responders and non-immune responders, is presented as
Kaplan–Meier plots in Figure 7B which clearly demonstrates that
the immune responders live longer than the non-responders. The
observed median survival was 7.2 months for the responders and
2.9 months for the non-responders (P¼0.001).
DISCUSSION
We here present results of the first clinical test of a novel, broadly
applicable, peptide-based cancer vaccine. The data show that
vaccination with GV1001 is safe and induces dose related cellular
immune responses that correlate with prolonged survival for
treatment naı ¨ve non-resectable pancreatic cancer patients. Telo-
merase vaccination has also been demonstrated to be safe by other
groups reporting clinical results from testing of hTERT mRNA-
transfected dendritic cell vaccination of patients with prostate
cancer (Su et al, 2005), and from vaccination of patients with
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after 3 days, are presented as mean c.p.m. of triplicates7s.d.. Similar bell
shaped curves were observed with other T-cell clones.
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Figure 6 (A) Recognition of recombinant hTERT by GV1001-specific T-
cell clone nos. 22 and 30 from patient no 102 and clone 51 from patient no
105. T cells (50000well
 1) were stimulated with 50000 irradiated
autologous EBV-transformed B cells as APC for 48h before labelling and
harvesting (see below). The APC were pulsed with either GV1001 (10mM)
or recombinant hTERT (3mM for clones 22 and 30 and 0.5mM for clone
51). T cells with APC alone served as negative controls. (B) Recognition of
ascites cells from patient 105 by T-cell clone nos 35 and 49 derived from
the same patient after vaccination. T cells (50000well
 1) were stimulated
for 48h with 50000 irradiated, T-cell depleted (anti-CD3-coated
Dynabeads) ascites cells or 50000 irradiated autologous EBV-transformed
B cells with or without GV1001 (25mM) as positive and negative controls.
After 48h of culture,
3H-thymidine was added and the cultures harvested
the next day. Results are expressed as mean c.p.m. of triplicate cultures.
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peptide (Parkhurst et al, 2004; Vonderheide et al, 2004).
The finding that 75% of the patients in the intermediate dose
group developed a T-cell response to the vaccine supports the
notion that GV1001 contains binding motifs that allows promis-
cuous binding to a broad array of HLA class II molecules. This
could be shown by cloning T cells from two of the responders
and testing their HLA restriction (Figure 1). This property
makes it unnecessary to tissue-type patients for HLA compliance
as an inclusion criterion, which is characteristic for many other
HLA allele-specific peptide cancer vaccines (i.e. HLA class I
epitopes).
Our results show that survival correlates with vaccine dose in a
statistically significant manner. The median survival for the
intermediate dose group, the group with the largest fraction of
immune responders, was 8.6 months, which was significantly
higher than for the two other dose groups. However, this is a small
non-randomised study and statistically significant differences
between groups must be interpreted with caution.
For the overall evaluable study population the median survival
for the immune responders (7.2 months) was significantly higher
than for the non-responders. The non-responder group will
contain patients with a shorter life expectancy than in the immune
responder group and many of these patients die within the first 90
days. However, it is interesting to observe that after 300 days, only
patients in the immune responding group are still alive. Booster
vaccination after end of study may have contributed to the survival
benefit by maintaining an anticancer immune response in some of
patients. Considering that non-resectable pancreatic cancer
patients normally are strongly immunosuppressed and have a
short life expectancy, the results are very encouraging. Gemcita-
bine treatment, which is the standard treatment in many countries,
generally results in a median survival of 4.8–5.6 months (Burris
et al, 1997; Storniolo et al, 1999).
One intriguing finding was that vaccination with the high dose
resulted in detection of a lower number of DTH responders than in
the intermediate dose group. An explanation may be that a very
high local concentration of peptide (5mM) may result in leakage of
peptide to surrounding tissue, uptake, and presentation of vaccine
by non-professional APCs. This can result in anergy of the specific
T cells or selection of T cells with low-affinity TcR or polarisation
of the T-cell response towards a Th2 response (Boyton and
Altmann, 2002) The peptide dose–response curve of the T-cell
clone depicted in Figure 5 demonstrate that high doses of peptide
results in a reduced T-cell response in vitro, indicating that similar
effects may be responsible for the weaker response to the high dose
after vaccination. This biphasic curve also has implications for the
interpretation of the immune responses observed. It is not only
conceivable that some samples that were scored negative would
have been positive with a higher peptide dose than that used in the
assay (25mM), but also the opposite scenario is conceivable. Some
samples could have scored negative because the peptide dose used
was too high.
GV1001 was capable of inducing CD4þ T helper (Th) cells in
the majority of the evaluable patients. These CD4þ T cells were
capable of recognising APCs pulsed with recombinant hTERT and
in one patient we also demonstrated that they recognised ascites
derived cells, clearly demonstrating that both exogenously and
endogenously derived hTERT is processed and presented in the
context of HLA class II molecules. The mechanism of action of Th
Days from the start of treatment
Low dose
Intermediate dose
High dose
0 100 200 300 400 500 600
0.00
0.25
0.50
0.75
1.00 A
0
Days from the start of treatment
Immune responders
Nonresponders
0.00
0.25
0.50
0.75
1.00
100 200 300 400 500 600
B
Figure 7 (A) Survival (Kaplan–Meier plot) of the evaluable patients treated with different doses of GV1001. Median survival (95% conf. int.): Low-dose
group (n¼8); 119 days (31–190), intermediate dose group (n¼16); 260 days (133–337), and high-dose group (n¼14); 153 days (106–249).
Intermediate vs low dose; P¼0.006, intermediate vs high dose; P¼0.05 (log-rank). (B) Survival (Kaplan–Meier plot) of all immune responders (n¼24) vs all
non-responders (n¼14) in the whole evaluable study population. Median survival (95% confidene interval) was; 216 days (146–323) for the immune
responders and 88 days (53–190) for the non-responders. P¼0.0001 (log-rank).
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scells in the antitumour response is complex and different from that
of tumour-specific CTLs. As most tumour cells do not express HLA
class II molecules, direct recognition of tumour cells does not take
place unless expression of class II molecules have been induced by
inflammatory cytokines locally. The cytokine profile generated
by the patients T cells after vaccination with GV1001 is highly
compatible with such a scenario, as both IFNg and TNFa was
produced (Figure 4A and B). Thus a supply of relevant cytokines
for polarisation of the T-cell response in the direction of a general
antitumour inflammatory response, giving rise to indirect killing
by CD4þ cells in HLA class II-negative tumours (Hung et al, 1998;
Janssen et al, 2003) may be part of the mechanism of action. The
observation of production of nanogram levels of IL13 is
interesting. Production of similar levels of IL13 in T cells in vitro
has been shown to be prognostic for the development of acute
graft-versus-host disease in patients who have received unrelated
donor stem cell transplantation (Jordan et al, 2004). Taken
together these data indicate that vaccination may direct potent
inflammatory response to the tumour itself or to tumour draining
lymph nodes. Induction of tumour-specific Th cells is considered
also to be mandatory for establishing and maintaining a clinically
efficient anticancer immune response caused by CTLs (Mumberg
et al, 1999; Schurmans et al, 2001) Vaccine induced Th cells, may
interact with professional APCs (i.e. dendritic cells) that have
engulfed dead tumour tissue, in situ in the tumour or in draining
lymph nodes. This interaction may give rise to a ‘second wave’ of
tumour reactive T cells, including CD8þ CTLs, that are directed
against unknown tumour/tissue-specific antigens (cross presenta-
tion) (Markiewicz et al, 2001). Furthermore Th cells also play an
important role in overcoming the immune-suppression caused by
regulatory CD4þCD25þ T cells (Casares et al, 2003).
The results encourage further and larger controlled clinical
studies with the intermediate dose of telomerase vaccine, GV1001,
in order to document the clinical benefits of the treatment
indicated by this study. The results should also open up for clinical
testing in patients with less tumour burden and longer life
expectancy than patients with advanced pancreatic cancer.
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